ArticleAnnals of surgical oncology2026
Axillary Pathologic Complete Response as a Stronger Prognostic Marker than Breast pCR in Clinically Node-Positive Stage II-III Breast Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathologic complete response (pCR) after neoadjuvant systemic therapy (NAST) predicts improved survival in breast cancer, but the relative prognostic value of breast versus axillary pCR in initially node-positive disease remains unclear.
methodsWe analyzed 455 patients with clinically node-positive stage II-III breast cancer treated with NAST (2010-2022). Patients were classified by breast-axilla response patterns: both-site pCR (n = 99), breast-only pCR (n = 24), axilla-only pCR (n = 117), and neither pCR (n = 215). The primary endpoint was invasive disease-free survival (IDFS); overall survival (OS) was secondary. Multivariable Cox models assessed prognostic associations adjusted for clinicopathologic covariates.
resultsMedian follow-up was 57.2 months; 135 IDFS events, and 118 deaths occurred. In head-to-head analysis, axillary pCR showed numerically stronger prognostic associations than breast pCR (IDFS adjusted hazard ratio [aHR] 0.441 vs. 0.501; OS aHR 0.373 vs. 0.544). Compared with neither pCR, both-site pCR (IDFS aHR 0.217, 95% confidence interval [CI] 0.12-0.394) and pooled discordant response patterns achieving one-site pCR (aHR 0.464, 95% CI 0.304-0.709) demonstrated favorable outcomes, whereas breast-only pCR, observed in small, underpowered subgroup (n = 24), did not show a statistically significant benefit (aHR 0.928, P = 0.849). Five-year IDFS was 89% (both-site pCR), 77% (axilla-only pCR), 65% (breast-only pCR), and 63% (neither pCR). Findings remained robust in sensitivity analyses restricted to biopsy-confirmed node-positive patients and ALND-only subsets.
conclusionsIn clinically node-positive breast cancer treated with NAST, axillary pCR showed numerically stronger prognostic associations than breast pCR, although this apparent difference should be interpreted cautiously. Post-neoadjuvant nodal status may help to refine risk stratification and inform adjuvant treatment planning.
Indexed as
Identifiers
42002715What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.